Rescue therapy in myasthenia gravis

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder.
• Fluctuating muscle weakness results from impaired neuromuscular transmission.
• Acute exacerbations and myasthenic crises pose significant clinical challenges despite current treatments.

Purpose of the Study:

• To provide a comprehensive overview of rescue therapies for myasthenia gravis.
• To detail the mechanisms, efficacy, and safety of established and novel acute MG treatments.
• To guide clinicians in optimizing rescue therapy for improved patient outcomes.

Main Methods:

• Review of established rescue therapies: Intravenous immunoglobulin (IVIG) and Plasma Exchange (PLEX).
• Discussion of emerging therapies: Eculizumab and Efgartigimod for acute MG management.
• Emphasis on personalized treatment strategies based on antibody status, disease severity, and comorbidities.

Main Results:

• Established therapies (IVIG, PLEX) provide crucial support during MG exacerbations.
• Novel agents (eculizumab, efgartigimod) show promise in managing acute phases of MG.
• Personalized approaches and vigilant monitoring are key to successful management.

Conclusions:

• Optimizing rescue therapy is essential for improving outcomes in myasthenia gravis acute exacerbations and crises.
• A combination of established and novel therapies, tailored to individual patient profiles, is crucial.
• Continued research and clinical vigilance are necessary for advancing MG crisis care.